Company · sight-sciences-inc-350a596d
Sight Sciences, Inc.
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. Sight Sciences, Inc. Companies, record sight-sciences-inc-350a596d. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/sight-sciences-inc-350a596d
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- Sight Sciences, Inc.
- Trials
- 19
- As lead sponsor
- 17
- As collaborator
- 2
- Recruiting
- 1
- Active, recruiting or not
- 4
- Completed
- 9
- Stopped early, withdrawn or suspended
- 6
- Posted results
- 14
- Trials by phase
- Phase 4 1
- Drugs its trials test
- 2
- Comparisons calculated in its trials
- 15
- First trial registered
- 2016-10-10
- Last update
- 2026-11-10
Source ClinicalTrials.gov
Pipeline2
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets | Source |
|---|---|---|---|---|---|---|---|---|
| LATANOPROST | Phase 4 | 1 | 1 | 0 | PTGFR | Prostanoid FP receptor agonist | https://conductscience.org/library/drugs/CHEMBL1051 | Open Targets |
| CYCLOSPORINE | Not applicable | 1 | 1 | 0 | PPIA | Cyclophilin A modulator | https://conductscience.org/library/drugs/CHEMBL160 | Open Targets |
Trials19
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07928986 | A Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | Collaborator | Recruiting | Observational | 36 | 2026-09-22 | https://conductscience.org/library/trials/NCT07928986 | ClinicalTrials.gov | |||
| NCT07579156 | TearCare in Young Adults | Collaborator | Not applicable | Not yet recruiting | Interventional | 45 | 2026-11-01 | https://conductscience.org/library/trials/NCT07579156 | ClinicalTrials.gov | ||
| NCT07365735 | TearCare MGX™ System With and Without Warming Hold | Lead sponsor | Not applicable | Completed | Interventional | 21 | 2026-03-17 | 2026-11-13 | https://conductscience.org/library/trials/NCT07365735 | ClinicalTrials.gov | |
| NCT06991270 | OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma | Lead sponsor | Not applicable | Active, not recruiting | Interventional | 25 | 2025-10-08 | https://conductscience.org/library/trials/NCT06991270 | ClinicalTrials.gov | ||
| NCT06948773 | A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX) | Lead sponsor | Not applicable | Active, not recruiting | Interventional | 25 | 2025-05-21 | https://conductscience.org/library/trials/NCT06948773 | ClinicalTrials.gov | ||
| NCT06407973 | A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma | Lead sponsor | Phase 4 | Terminated | Interventional | 2 | 2024-08-21 | LATANOPROST | https://conductscience.org/library/trials/NCT06407973 | ClinicalTrials.gov | |
| NCT05044793 | A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System | Lead sponsor | Completed | Observational | 70 | 2021-09-01 | 2025-01-22 | https://conductscience.org/library/trials/NCT05044793 | ClinicalTrials.gov | ||
| NCT04872348 | An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0) | Lead sponsor | Completed | Observational | 28 | 2021-07-01 | 2025-05-11 | https://conductscience.org/library/trials/NCT04872348 | ClinicalTrials.gov | ||
| NCT04795752 | Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA) | Lead sponsor | Not applicable | Completed | Interventional | 345 | 2021-04-28 | 2025-11-24 | CYCLOSPORINE | https://conductscience.org/library/trials/NCT04795752 | ClinicalTrials.gov |
| NCT04658095 | Study of OMNI Surgical System and iStent for Eyes With OAG (Trident) | Lead sponsor | Not applicable | Terminated | Interventional | 10 | 2022-01-11 | 2025-10-27 | https://conductscience.org/library/trials/NCT04658095 | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsConditions10
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Glaucoma, Open-Angle | 5 |
| Dry Eye | 4 |
| Meibomian Gland Dysfunction (Disorder) | 3 |
| Primary Open Angle Glaucoma | 3 |
| Dry Eye Syndromes | 2 |
| Meibomian Gland Dysfunction | 2 |
| Cataract | 1 |
| Dry Eye Syndrome (DES) | 1 |
| Open Angle Glaucoma | 1 |
| Open-Angle Glaucoma | 1 |
Source ClinicalTrials.gov
Partners2
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
| Organization | Class | Trials shared | In Companies | Source |
|---|---|---|---|---|
| Cleveland Eye Clinic | Other | 1 | ClinicalTrials.gov | |
| University of Alabama at Birmingham | Other | 1 | ClinicalTrials.gov |
Data dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/sight-sciences-inc-350a596d
GET https://conductscience.org/api/companies/v1/sight-sciences-inc-350a596d/pipeline